Subscribe To

Price Alert Latest News Economic Calendar News

VERU / Why Veru Stock Is Skyrocketing Today

Investors are reacting positively to an FDA briefing document. Read More

Demo Live Account See Partner Details

Content Topics

Today

Posted: Nov 7 2022, 11:47

Author Name: The Motley Fool

VERU News

By Zacks Investment Research
August 10, 2023

Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates

Veru Inc. (VERU) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0

By Seeking Alpha
May 11, 2023

Veru Inc. (VERU) Q1 2023 Earnings Call Transcript

Veru Inc. (NASDAQ:VERU ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relati

By Zacks Investment Research
May 11, 2023

Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates

Veru Inc. (VERU) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0

By InvestorPlace
May 11, 2023

VERU Stock Earnings: Veru Misses EPS, Beats Revenue Estimates

Veru (NASDAQ: VERU ) just reported its fiscal second-quarter results. Veru reported a loss per share of 43 cents.

By Zacks Investment Research
May 9, 2023

Is a Surprise Coming for Veru (VERU) This Earnings Season?

Veru (VERU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

By InvestorPlace
April 21, 2023

Why Is VERU Stock Up 3% Today?

Veru (NASDAQ: VERU ) stock is getting a boost on Friday after the company revealed plans to sell its ENTADFI capsule business. That sale has the compa

By GlobeNewsWire
March 7, 2023

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-1

By InvestorPlace
March 3, 2023

Why Is Veru (VERU) Stock Down 37% Today?

Veru (NASDAQ: VERU ) stock is taking a beating on Friday after the FDA denied the company's request for EUA for its Covid-19 treatment. That rejection

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.